Q1 Report 2018

GLPG1690, a potent and selective inhibitor of autotaxin, a potential target for IPF.

Financial highlights

Group revenues

44.8 million

Read more

Cash position

1108.2 million

Read more

Letter from the management

We continue to expand our organization to be able to execute the increasing number of clinical studies and to be ready for the anticipated market introduction of our drug candidates.
Read more